PROTOCOLOS CLÍNICOS E DIRETRIZES TERAPÊUTICAS

Protocolos Clínicos e Diretrizes Terapêuticas 12 T ermo de esclarecimento e responsabilidade – TER É obrigatória a informação ao paciente ou a seu responsável legal sobre potenciais riscos, benefícios e efeitos adversos relacionados ao uso dos medicamentos preconizados neste protocolo. O TER é obrigatório ao se prescrever medicamento do Componente Especializado da Assistência Farmacêutica. 13 R eferências bibliográficas 1. Souza LM, Boone TC, Gabrilove J, Lai PH, Zsebo KM, Murdock DC, et al. Recombinant human granulocyte colony- stimulating factor: effects on normal and leukemic myeloid cells. Science. 1986;232(4746):61-5. 2. Metcalf D. The colony stimulating factors. Discovery, development, and clinical applications. Cancer. 1990;65(10):2185-95. 3. Lyman GH, Kuderer NM. Filgrastim in patients with neutropenia: potential effects on quality of life. Drugs. 2002;62(Suppl 1):65- 78. 4. Lyman GH, Kuderer NM. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Crit Rev Oncol Hematol. 2004;50(2):129-46. 5. Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol. 2000;18(20):3558-85. 6. Geissler K, Koller E, Hubmann E, Niederwieser D, Hinterberger W, Geissler D, et al. Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia – a randomized phase-III study. Blood. 1997;90(2):590-6. 7. Laver J, Amylon M, Desai S, Link M, Schwenn M, Mahmoud H, et al. Randomized trial of r-metHu granulocyte colony- stimulating factor in an intensive treatment for T-cell leukemia and advanced-stage lymphoblastic lymphoma of childhood: a Pediatric Oncology Group pilot study. J Clin Oncol. 1998;16(2):522-6. 8. Ottmann OG, Hoelzer D, Gracien E, Ganser A, Kelly K, Reutzel R, et al. Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: a randomized phase III trial. Blood. 1995;86(2):444-50. 9. Pui CH, Boyett JM, Hughes WT, Rivera GK, Hancock ML, Sandlund JT, et al. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med. 1997;336(25):1781-7. 10. Scherrer R, Geissler K, Kyrle PA, Gisslinger H, Jäger U, BettelheimP, et al. Granulocyte colony-stimulating factor (G-CSF) as an adjunct to induction chemotherapy of adult acute lymphoblastic leukemia (ALL). Ann Hematol. 1993;66(6):283-9. 11. Sung L, Nathan PC, Lange B, Beyene J, Buchanan GR. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials. J Clin Oncol. 2004;22(16):3350-6. 12. Welte K, Reiter A, Mempel K, Pfetsch M, Schwab G, Schrappe M, et al. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Munster Study Group. Blood. 1996;87(8):3143-50. 13. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34(6):730-51. Epub 2002 Feb 13. 14. Dale DC, Cottle TE, Fier CJ, Bolyard AA, Bonilla MA, Boxer LA, et al. Severe chronic neutropenia: treatment and follow- up of patients in the Severe Chronic Neutropenia International Registry. Am J Hematol. 2003;72(2):82-93. 15. Zeidler C, Boxer L, Dale DC, Freedman MH, Kinsey S, Welte K. Management of Kostmann syndrome in the G-CSF era. Br J Haematol. 2000;109(3):490-5. 16. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64(2):328-40. 17. Donowitz GR, Maki DG, Crnich CJ, Pappas PG, Rolston KV. Infections in the neutropenic patient – new views of an old problem. Hematology Am Soc Hematol Educ Program. 2001:113-39. 18. García-Carbonero R, Mayordomo JI, Tornamira MV, López-Brea M, Rueda A, Guillem V, et al. Granulocyte colony- stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst. 2001;93(1):31-8. 19. Klaassen RJ, Goodman TR, Pham B, Doyle JJ. “Low-risk” prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol. 2000;18(5):1012-9. 20. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J 44